# US 2025/0163489 A1 · Enzymes and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0163489 A1
- Document ID: US20250163489A1
- Status: Published application
- Kind: A1
- Application number: 18/842,674
- Filed: 2023-03-01
- Published: 2025-05-22
- Earliest claimed: 2022-03-02
- Applicants: University of Newcastle upon Tyne; The University of Birmingham
- Inventors: Elisabeth LOWE; Patrick MOYNIHAN; Joseph MANION; Amar GUDKA
- Web page: https://patentgrep.com/patent/US20250163489A1

## CPC

- C12Q 1/04: Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor {(C12Q1/6897 takes precedence)}
- C12Y 302/01146: Beta-galactofuranosidase (3.2.1.146)
- A61P 31/04: Antibacterial agents
- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- C12Q 1/34: involving hydrolase
- C12Q 1/40: involving amylase
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G01N 2333/35: from Mycobacteriaceae (F)
- G01N 2333/36: from Actinomyces; from Streptomyces (G)
- G01N 2333/924: acting on glycosyl compounds (3.2)
- G01N 2333/938: acting on beta-galactose-glycoside bonds, e.g. beta-galactosidase
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides uses of enzymes for cleaving a linkage between two D-galactofuranoses and/or two D-arabinofuranoses in a polysaccharide. An example of a polysaccharide where such linkages are present is arabinogalactan. The invention also provides compositions comprising said enzymes, as well as methods for preparing a sample, and methods for determining the presence of a bacterium of the Actinomycetota phylum in a sample using said enzymes. Additionally, the invention provides pharmaceutical formulations comprising a composition of the invention, as well as uses of the pharmaceutical formulations as a medicament, for example to treat a bacterial infection caused by a bacterium of the Actinomycetota phylum.

## Claims

### Claim 1

Use of an enzyme for cleaving a linkage between two D-galactofuranoses in a polysaccharide, wherein the enzyme comprises an amino acid sequence having at least 70% sequence identity to a sequence provided in Table 1.

### Claim 2 (depends on 1)

Use according to claim 1, wherein the enzyme is an exo-D-galactofuranosidase, and the enzyme comprises an amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2; or an amino acid sequence which has at least 70% sequence identity thereto.

### Claim 3 (depends on 2)

Use according to claim 2, wherein the exo-D-galactofuranosidase comprises an amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2.

### Claim 4 (depends on 1)

Use according to claim 1, wherein the enzyme is an endo-D-galactofuranase, and the enzyme comprises an amino acid sequence as shown in SEQ ID NO: 3; or an amino acid sequence which has at least 70% sequence identity thereto.

### Claim 5 (depends on 4)

Use according to claim 4, wherein the endo-D-galactofuranase comprises an amino acid sequence as shown in SEQ ID NO: 3.

### Claim 6 (depends on 1, 2, 3, 4, 5)

Use according to any one of claims 1 to 5, wherein the polysaccharide is a D-galactofuranose polysaccharide.

### Claim 7

Use of an enzyme for cleaving a linkage between two D-arabinofuranoses in a polysaccharide, wherein the enzyme comprises an amino acid sequence having at least 70% sequence identity to a sequence provided in Table 2.

### Claim 8 (depends on 7)

Use according to claim 7, wherein the enzyme is an endo-D-arabinofuranase, and the enzyme comprises an amino acid sequence as shown in SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9; or an amino acid sequence which has at least 70% sequence identity thereto.

### Claim 9 (depends on 8)

Use according to claim 8, wherein the endo-D-arabinofuranase comprises an amino acid sequence as shown in SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9.

### Claim 10 (depends on 7)

Use according to claim 7, wherein the enzyme is an exo-D-arabinofuranosidase, and the enzyme comprises an amino acid sequence as shown in SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 14; or an amino acid sequence which has at least 70% sequence identity thereto.

### Claim 11 (depends on 10)

Use according to claim 10, wherein the exo-D-arabinofuranosidase comprises an amino acid sequence as shown in SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 14.

### Claim 12 (depends on 7, 8, 9, 10, 11)

Use according to any one of claims 7 to 11, wherein the polysaccharide is lipoarabinomannan (LAM) or pilin oligosaccharide.

### Claim 13 (depends on 1, 2, 3, 4, 5)

Use according to any one of claims 1 to 5, or 7 to 11 wherein the polysaccharide is arabinogalactan.

### Claim 14

Use according to any proceeding claim, wherein the polysaccharide is a bacterial cell wall polysaccharide.

### Claim 15 (depends on 14)

Use according to claim 14, wherein the bacterial cell wall polysaccharide is from a bacterium of the Actinomycetota phylum.

### Claim 16 (depends on 15)

Use according to claim 15, wherein the bacterium is of the Mycobacteriales order.

### Claim 17 (depends on 16)

Use according to claim 16, wherein the bacterium is of the family selected from the group consisting of: Segniliparaceae, Mycobacteriaceae, Nocardiaceae, Tsukamurellaceae, Gordoniaceae, Lawsonellaceae, Corynebacteriaceae and Dietziaceae.

### Claim 18 (depends on 17)

Use according to claim 17, wherein the bacterium is of the family Mycobacteriaceae.

### Claim 19 (depends on 18)

Use according to claim 18, wherein the bacterium is selected from the group consisting of M. tuberculosis, M. bovis, M. africanum, M. canetti, M. microti. M. smegmatis, M. fortuitum, M. marinum, M. ulcerans, M. paratuberculosis, M. celatum, M. avium, M. leprae, M. lepraemurium, M. intracellulare M. scrofulaceum, M. xenopi, M. genavense, M. kansasii, M. simiae, M. szulgai, M. haemophilum, M. asiaticum, M. malmoense, M. vaccae, M. caprae, M. pinnipe dii and M. shimoidei.

### Claim 20

A composition for degrading a Actinomycetota bacterial cell wall polysaccharide, wherein the composition comprises at least two bacterial cell wall degrading enzymes, wherein at least one of the at least two cell wall degrading enzymes is an enzyme comprising an amino acid sequence as shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10; or an amino acid sequence which has at least 70% sequence identity thereto.

### Claim 21 (depends on 20)

The composition according to claim 20, wherein the composition comprises:
a) at least one enzyme comprising an amino acid sequence as shown in SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3; or an amino acid sequence which has at least 70% sequence identity thereto; and
b) at least one enzyme comprising an amino acid sequence as shown in SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10;
or an amino acid sequence which has at least 70% sequence identity thereto.

### Claim 22 (depends on 20, 21)

The composition according to claim 20 or 21, wherein the composition comprises an exo-D-galactofuranosidase comprising an amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2; or an amino acid sequence which has at least 70% sequence identity thereto.

### Claim 23 (depends on 20, 21, 22)

The composition according to any one of claims 20 to 22, wherein the composition comprises an endo-D-galactofuranase comprising an amino acid sequence as shown in SEQ ID NO: 3; or an amino acid sequence which has at least 70% sequence identity thereto.

### Claim 24 (depends on 20, 21, 22, 23)

The composition according to any one of claims 20 to 23, wherein the composition comprises an endo-D-arabinofuranase comprising an amino acid sequence as shown in SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6; or an amino acid sequence which has at least 70% sequence identity thereto.

### Claim 25 (depends on 20, 21, 22, 23, 24)

The composition according to any one of claims 20 to 24, wherein the composition comprises an exo-D-arabinofuranosidase comprising an amino acid sequence as shown in SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10; or an amino acid sequence which has at least 70% sequence identity thereto.

### Claim 26 (depends on 20, 21, 22, 23, 24, 25)

The composition according to any one of claims 20 to 25, wherein the composition comprises:
(i) an exo-D-galactofuranosidase comprising an amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2; or an amino acid sequence which has at least 70% sequence identity thereto;
(ii) an endo-D-galactofuranase comprising an amino acid sequence as shown in SEQ ID NO: 3; or an amino acid sequence which has at least 70% sequence identity thereto; and
(iii) an endo-D-arabinofuranase comprising an amino acid sequence as shown in SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6; or an amino acid sequence which has at least 70% sequence identity thereto.

### Claim 27 (depends on 26)

The composition according to claim 26, further comprising an exo-D-arabinofuranosidase comprising an amino acid sequence as shown in SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10; or an amino acid sequence which has at least 70% sequence identity thereto.

### Claim 28 (depends on 20, 21, 22, 23, 24, 25, 26, 27)

The composition according to any one of claims 20 to 27, wherein the composition comprises:
(i) an exo-D-galactofuranosidase comprising an amino acid sequence as shown in SEQ ID NO: 1 and/or SEQ ID NO: 2; or an amino acid sequence which has at least 70% sequence identity thereto;
(ii) an endo-D-galactofuranase comprising an amino acid sequence as shown in SEQ ID NO: 3; or an amino acid sequence which has at least 70% sequence identity thereto;
(iii) an endo-D-arabinofuranase comprising an amino acid sequence as shown in SEQ ID NO: 5 and/or SEQ ID NO: 6; or an amino acid sequence which has at least 70% sequence identity thereto; and
(iv) an exo-D-arabinofuranosidase comprising an amino acid sequence as shown in SEQ ID NO: 8 and/or SEQ ID NO: 10; or an amino acid sequence which has at least 70% sequence identity thereto.

### Claim 29 (depends on 28)

The composition according to claim 28, wherein the composition comprises:
(i) an exo-D-galactofuranosidase comprising an amino acid sequence as shown in SEQ ID NO: 1 and/or SEQ ID NO: 2;
(ii) an endo-D-galactofuranase comprising an amino acid sequence as shown in SEQ ID NO: 3;
(iii) an endo-D-arabinofuranase comprising an amino acid sequence as shown in SEQ ID NO: 5 and/or SEQ ID NO: 6; and
(iv) an exo-D-arabinofuranosidase comprising an amino acid sequence as shown in SEQ ID NO: 8 and/or SEQ ID NO: 10.

### Claim 30 (depends on 29)

The composition according to claim 29, wherein the composition comprises:
(i) an exo-D-galactofuranosidase comprising an amino acid sequence as shown in SEQ ID NO: 1;
(ii) an endo-D-galactofuranase comprising an amino acid sequence as shown in SEQ ID NO: 3;
(iii) an endo-D-arabinofuranase comprising an amino acid sequence as shown in SEQ ID NO: 5 and SEQ ID NO: 6; and
(iv) an exo-D-arabinofuranosidase comprising an amino acid sequence as shown in SEQ ID NO: 8 and SEQ ID NO: 10.

### Claim 31 (depends on 20, 21, 22, 23, 24, 25, 26)

The composition according to any one of claims 20 to 26, wherein the composition comprises an exo-D-arabinofuranosidase comprising an amino acid sequence as shown in SEQ ID NO: 11 and/or SEQ ID NO: 13; or an amino acid sequence which has at least 70% sequence identity thereto.

### Claim 32 (depends on 31)

The composition according to claim 31, wherein the composition comprises:
(v) an exo-D-galactofuranosidase comprising an amino acid sequence as shown in SEQ ID NO: 1; or an amino acid sequence which has at least 70% sequence identity thereto;
(vi) an endo-D-galactofuranase comprising an amino acid sequence as shown in SEQ ID NO: 3; or an amino acid sequence which has at least 70% sequence identity thereto;
(vii) an endo-D-arabinofuranase comprising an amino acid sequence as shown in SEQ ID NO: 6; or an amino acid sequence which has at least 70% sequence identity thereto; and
(viii) an exo-D-arabinofuranosidase comprising an amino acid sequence as shown in SEQ ID NO: 11 and/or SEQ ID NO: 13; or an amino acid sequence which has at least 70% sequence identity thereto.

### Claim 33 (depends on 32)

The composition according to claim 32, wherein the composition comprises:
(v) an exo-D-galactofuranosidase comprising an amino acid sequence as shown in SEQ ID NO: 1;
(vi) an endo-D-galactofuranase comprising an amino acid sequence as shown in SEQ ID NO: 3;
(vii) an endo-D-arabinofuranase comprising an amino acid sequence as shown in SEQ ID NO: 6; and
(viii) an exo-D-arabinofuranosidase comprising an amino acid sequence as shown in SEQ ID NO: 11 and SEQ ID NO: 13.

### Claim 34 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The composition according to any one of claims 20 to 33, wherein the composition is freeze dried.

### Claim 35 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The composition according to any one of claims 20 to 34, wherein the second of the at least two cell wall degrading enzymes is selected from the group consisting of a peptidoglycan degrading enzyme, a mycolic acid degrading enzyme, a lipoarabinomannan degrading enzyme, and a pilin oligosaccharide degrading enzyme.

### Claim 36 (depends on 35)

The composition according to claim 35, wherein the mycolic acid degrading enzyme is lysin B or a Candida rugosa lipase.

### Claim 37 (depends on 35, 36)

The composition according to claim 35 or 36, wherein the peptidoglycan degrading enzyme is a lysozyme, optionally hen-egg white lysozyme.

### Claim 38 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

Use of a composition according to any one of claims 21 to 37, for cleaving a linkage between two D-galactofuranoses and/or cleaving a linkage between two D-arabinofuranoses in a polysaccharide.

### Claim 39 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

A method for preparing a sample for the detection of a bacterium of the Actinomycetota phylum, the method comprising contacting the sample with a composition according to any one of claims 21 to 37 under conditions that allow for degradation of Actinomycetota bacterial cell wall polysaccharides to occur.

### Claim 40 (depends on 39)

The method according to claim 39, wherein the method lyses the bacteria in the sample.

### Claim 41 (depends on 39, 40)

A method of determining the presence of a bacterium of the Actinomycetota phylum in a sample, comprising:
(i) providing a sample prepared according to claim 39 or 40; and
(ii) detecting a biomarker indicative of the presence of the bacterium in the sample.

### Claim 42 (depends on 41)

The method of claim 41, wherein the biomarker is a nucleic acid, protein, carbohydrate, and/or a lipid.

### Claim 43 (depends on 39, 40, 41, 42)

The method according to any one of claims 39 to 42, wherein the sample is selected from the group consisting of a sputum sample, a blood sample, a stool sample and a urine sample.

### Claim 44 (depends on 39, 40, 41, 42, 43)

The method according to any one of claims 39 to 43, wherein the bacterium is of the Mycobacteriales order.

### Claim 45 (depends on 44)

The method according to claim 44, wherein the bacterium is of the family selected from the group consisting of: Segniliparaceae, Mycobacteriaceae, Nocardiaceae, Tsukamurellaceae, Gordoniaceae, Lawsonellaceae, Corynebacteriaceae and Dietziaceae.

### Claim 46 (depends on 45)

The method according to claim 45, wherein the bacterium is of the family Mycobacteriaceae, optionally wherein the bacterium is selected from the group consisting of M. tuberculosis, M. bovis, M. africanum, M. canetti, M. microti. M. smegmatis, M. fortuitum, M. marinum, M. ulcerans, M. paratuberculosis, M. celatum, M. avium, M. leprae, M. lepraemurium, M. intracellulare M. scrofulaceum, M. xenopi, M. genavense, M. kansasii, M. simiae, M. szulgai, M. haemophilum, M. asiaticum, M. malmoense, M. vaccae, M. caprae, M. pinnipe dii and M. shimoidei.

### Claim 47 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

A pharmaceutical formulation comprising a composition according to any one of claims 20 to 37, and a pharmaceutically acceptable excipient carrier, adjuvant, and/or diluent.

### Claim 48 (depends on 47)

The pharmaceutical formulation according to claim 47, wherein the formulation is for pulmonary delivery and/or topical administration.

### Claim 49 (depends on 47, 48)

A pharmaceutical formulation according to claim 47 or 48 for use as a medicament.

### Claim 50 (depends on 47, 48)

A pharmaceutical formulation according to claim 47 or 48 for use in treating a bacterial infection caused by a bacterium of the Actinomycetota phylum.

### Claim 51 (depends on 50)

The pharmaceutical formulation for use according to claim 50, wherein the infection is a mycobacterial infection.

### Claim 52 (depends on 47, 48)

A method of treating a bacterial infection caused by bacterium of the Actinomycetota phylum in a subject, comprising administering a therapeutically effective amount of the pharmaceutical formulation according to claim 47 or 48 to a subject in need thereof.

### Claim 53 (depends on 52)

The method according to claim 52, wherein the infection is a mycobacterial infection.
